Leucocyte migration inhibition test in coeliac disease – a reappraisal

F G SIMPSON, H P FIELD, P D HOWDLE, D A F ROBERTSON, AND M S LOSOWSKY

From the Department of Medicine, St James's University Hospital, Leeds

SUMMARY Results of the direct leucocyte migration inhibition (LMI) test using gluten fraction III as antigen were unaffected by incorporation of puromycin into the culture medium at concentrations shown to prevent lymphokine mediated inhibition. Results of the LMI test performed with purified polymorphs were similar to and correlated with results of the standard LMI test using mixed leucocytes in both coeliacs and controls. The addition of purified T lymphocytes did not increase migration inhibition. Normal leucocytes incubated with serum from coeliac patients and washed showed marked migration inhibition when incubated with gluten fraction III. This sensitisation of normal leucocytes was prevented by preincubation with aggregated human IgG. These results suggest that leucocyte migration inhibition by gluten in coeliac disease is not due to lymphokine production by sensitised lymphocytes but is caused by cytophilic antibody.

There is considerable evidence for abnormal immunity to gluten in patients with coeliac disease and it is suggested that this may be important in pathogenesis. In recent years attention has been focused on the role of cell mediated immunity to gluten and much of the evidence supporting the existence of such immunity comes from use of the leucocyte migration inhibition (LMI) test. In its simplest form this test involves incubation of peripheral blood leucocytes with the putative antigen and comparison of the migration of these leucocytes with those cultured in control medium. Inhibition of migration in the presence of antigen is taken to represent production of lymphokines by T lymphocytes specifically reactive to the antigen and thus to provide a measure of cell mediated immunity. In general the correlation between results of the LMI test and delayed hypersensitivity shown by skin testing has been good for antigens such as purified protein derivative where the importance of cellular immunity is clear. Inhibition of leucocyte or macrophage migration, however, may be produced by factors elaborated by B lymphocytes and other cell types by cytophilic antibody, by immune complexes and by direct toxicity of the putative antigen. Furthermore, skin tests with gluten subfractions have shown no evidence of delayed hypersensitivity to gluten in coeliac disease. We have therefore further investigated the LMI test in coeliac disease using puromycin as an inhibitor of lymphokine production and using purified white cell populations to determine whether or not the assumption that results of the LMI test correlate with T-lymphocyte mediated immunity to gluten is justified. We have also investigated the possibility that a serum factor such as cytophilic antibody is involved by attempting to sensitise normal leucocytes to gluten by preincubation with sera from coeliac patients.

Methods

Patients

Ten patients (seven women and three men) with coeliac disease were studied. All had typical jejunal biopsy changes at the time of diagnosis and all showed histological improvement on gluten exclusion. Mean age was 25 years (range 12–53 years). Five patients were studied while taking a normal diet and the other five had been on a gluten free diet for at least six months (mean 11 months). The eight healthy controls (mean age 30 years) were hospital personnel.
ANTIGENS
Gluten fraction III was prepared according to the method of Frazer et al and was used at a final concentration of 1 mg/ml in the LMI test. As a positive control purified protein derivative was used. Five normal controls were Mantoux-tested with 1 IU of purified protein derivative intradermally. The diameter of induration produced was measured at 24 hours. Induration of greater than 10 mm diameter was taken as a positive response. Cells from the five controls were used in LMI tests with preservative free purified protein derivative (Ministry of Agriculture, Weybridge, Surrey) at a final concentration of 200 μg/ml.

LEUCOCYTE SEPARATION
Leucocytes were prepared from defibrinated venous blood for the LMI test by dextran sedimentation for 30 minutes as previously described. Differential white cell counts on leucocytes prepared in this fashion showed a mean of 63% polymorphs, 33% lymphocytes, and 4% eosinophils and monocytes.

SEPARATION OF LEUCOCYTE SUBPOPULATIONS
Mononuclear cells were separated from heparinised venous blood by centrifugation at 400 g for 30 minutes through Histopaque 1077 (Sigma Chemicals). Mean yield of mononuclear cells from 30 ml of blood was 3.2 x 10^7 cells. Differential counts showed more than 95% lymphocytes with the remainder monocytes. The red cell pellets from beneath the Histopaque were combined and allowed to sediment for 20 minutes at 37°C and the polymorph-rich supernate removed. Mean yield of polymorphs was 3.14 x 10^7 cells. Leishman stained smears of these preparations showed more than 99% polymorphs with occasional eosinophils and no mononuclear cells. Aliquots of the mononuclear cell preparations were taken for use in the LMI test and the remainder used for separation into T and B cells. This was achieved by rosetting with neuraminidase treated sheep red blood cells (n-SRBC). Two millilitres of 2% n-SRBC were mixed with the mononuclear cells and spun at 1000 rpm for five minutes. After one hour at room temperature the cell pellet was gently resuspended and 1.15 ml Histopaque introduced carefully under the cells with a Pasteur pipette. After centrifugation at 1800 rpm for 20 minutes the rosetted T cells were pelleted under the Histopaque and the non-rosetted cells at the medium-Histopaque interface. The SRBC were removed from the T cells with 0.8% ammonium chloride. All cell preparations were washed twice in medium before use in the LMI test. Cell viabilities were always over 99% as judged by trypan blue exclusion. The effectiveness of the T-B separation was checked periodically by re-rosetting using n-SRBC for T cells and with chromic chloride treated fresh ox erythrocytes conjugated with antihuman immunoglobulin for B cells. The T cell enriched preparation always contained more than 92% T cells and less than 5% B cells and the B cell enriched preparation more than 54% B cells (usually more than 70%) with less than 10% T cells. Mean recovery of cells from the rosetting procedure was 76%.

LMI TEST
This was performed by a capillary tube method as previously described. The areas of leucocyte migration were measured at 20 hours by planimetry of traced projected images of the cultures and migration index calculated as:

\[
\text{Migration index} = \frac{\text{Mean area of migration in the presence of antigen}}{\text{Mean area of migration in control medium}}
\]

When using mixtures of polymorphs and lymphocytes these were mixed in the proportion 2:1 to reproduce the approximate proportions of cells in the dextran sedimented leucocytes used in the standard test. The effect of puromycin at a final concentration of 15 μg/ml on leucocyte migration in the presence and absence of antigen was tested on six coeliacs and six controls with gluten fraction III as antigen and five controls with purified protein derivative as antigen.

SERUM INCUBATION
To investigate whether a serum factor might be involved in sensitising leucocytes to gluten the LMI test was performed with cells obtained by dextran sedimentation from a normal control which were incubated at 37°C for one hour with sera from six of the coeliac patients at a dilution of one half. The cells were then washed twice in cold medium and used in the LMI test as usual. Aliquots of the cells were also preincubated with aggregated human IgG to attempt to block Fc receptors. The IgG (at 64 mg/ml) was aggregated by heating to 63°C for 20 minutes and incubated with the cells for one hour at 37°C at a final concentration of 5-8 mg/ml. The cells were then washed twice in cold medium and incubated with coeliac serum as above, rewashed twice and used in the LMI test.

RESULTS
The effect of puromycin at 15 μg/ml on migration indices with gluten fraction III as antigen is shown in Fig. 1. With puromycin there is no trend towards increasing migration indices to approach unity as
Leucocyte migration inhibition test in coeliac disease

would be expected if a lymphokine were involved. This contrasts with the effect of puromycin on migration index with purified protein derivative as antigen (Fig. 2). With purified protein derivative alone the three Mantoux-positive subjects all showed migration inhibition which in each case was reduced by puromycin. Puromycin did not affect migration indices of the Mantoux-negative subjects. Absolute migration areas of cultures performed with puromycin alone (without antigen) did not differ significantly from those in culture medium without additives.

Figure 3 illustrates the comparison of migration indices using gluten fraction III in the standard LMI test and in the LMI test performed with polymorphs alone, mononuclear cells alone, and with polymorphs with added T cells and with added B cells. (On some occasions the yield of mononuclear cells or B cells was insufficient to allow the setting up of quadruplicate cultures and the numbers in these experiments are thus reduced.) With the standard LMI test the coeliac patients show a significant reduction of migration index compared with controls (p<0.05 by Wilcoxon's rank sum test). A similar difference is observed in the test performed with purified polymorphs. Mononuclear cells alone were not inhibited either in coeliacs or controls. When the test was performed with polymorphs with added T cells or with added B cells results were similar to those with polymorphs alone, although the difference between coeliacs and controls fails to reach statistical significance in each case. There were no significant differences between results from treated and untreated coeliacs in these experiments in contrast with previous findings: this probably reflects the small numbers studied.

Figure 4 shows the correlation between individual migration indices to gluten fraction III using the standard LMI test and that performed with purified polymorphs. There is a significant correlation between the results of the two tests using both parametric and non-parametric tests (r=0.62, t=3.2, p<0.01; Spearman's rank correlation coefficient=0.64, p<0.01). Furthermore, the slope of the line of best fit is 0.91 with a standard deviation of the slope of 0.28. The slope therefore does not differ significantly from unity (t=0.33) nor does the intercept differ significantly from zero (y intercept=0.13, SD=0.24, t=0.53).

These results contrast with those shown in Fig. 5 in which migration indices to purified protein derivative are shown using the standard LMI test and the test performed with the same cell types as in Fig. 3. In this case significant migration inhibition of cells from Mantoux-positive subjects is seen only in the standard test and with the combination of

---

**Fig. 1** Effect of puromycin on migration indices with gluten fraction III as antigen in normal controls and coeliac patients.

**Fig. 2** Effect of puromycin on migration indices with purified protein derivative as antigen.
polymorphs and T cells. Polymorphs alone are not inhibited.

The effect of incubation of normal cells with serum from coeliac patients and of preincubation with aggregated IgG before incubation with coeliac serum is shown in Fig. 6. Cells from this normal control subject consistently give a migration index of around 0.9 with gluten fraction III as antigen (mean of four experiments 0.91, SD 0.02). After incubation with coeliac sera and washing, however, the cells were markedly inhibited by gluten fraction III (mean migration index 0.75, SD 0.05). This sensitisation to gluten was prevented by incubation with aggregated IgG before the incubation with coeliac sera (mean migration index 0.89, SD 0.05).

Discussion

The use of the LMI test as an assay of cell mediated immunity relies on the correlation between results of the test with results of skin tests for delayed hypersensitivity. In the absence of such a correlation, as in coeliac disease, it is necessary to examine critically the mechanisms which may be producing migration inhibition.

Puromycin and other protein synthesis inhibitors have been shown in several studies to block lymphokine mediated migration inhibition.8 19 23 The mechanism of action of puromycin is not understood; there is some evidence that it acts on the target cell to render it unreactive to lymphokine rather than on lymphokine release by the lymphocyte.18 The lack of effect in this study argues against the role of lymphokines in the migration inhibition produced by gluten. The concentration of puromycin used is similar to that in previous studies and is shown to be sufficient by its effect on migration index to purified protein derivative in the Mantoux-positive controls. The lack of effect of
puromycin with gluten as antigen is in accord with our previous findings when jejunal biopsies from coeliac patients were cultured with gluten and continued to produce soluble inhibitors of leucocyte migration in the presence of puromycin.24

The demonstration that purified polymorphs from coeliac patients are inhibited by gluten is strong evidence against the role of lymphokine in producing migration inhibition in this system and suggests that either cytophilic antibody or direct toxicity of the antigen is involved. The latter cannot be completely excluded, although dose-response studies have shown no increased susceptibility of coeliac leucocytes to decreased viability when cultured with gluten fraction III (Simpson, unpublished observations). The addition of T lymphocyte enriched cell suspensions to the polymorphs failed to increase the degree of migration inhibition, again suggesting that lymphocyte products are not contributing significantly to inhibition of migration of the polymorphs. This contrasts with the results with purified protein derivative where the polymorphs alone are unaffected but the addition of the T cell preparation produces migration inhibition in the Mantoux-positive subjects.

The sensitisation of normal leucocytes to gluten-induced migration inhibition by incubation with serum from coeliac patients suggests that cytophilic antibody may be what is being measured in the LMI test as we have performed it. Inhibition of leucocyte or macrophage migration by cytophilic antibody has been shown by several groups of workers.11-16 The existence of antibodies which bind to phagocytic cells and modify their immune capabilities has been known for many years.25 Most of the experimental data concern macrophage-cytophilic antibody.25-27 Although similar antibodies which bind to polymorphs and modify their antigen binding and phagocytic capabilities have been described in animals28 29 and there is some evidence that the IgG subclasses IgG1 and IgG3 in man bind to polymorphs as well as to monocytes.30 Cytophilic antibody binds to cells via

---

**Fig. 5** Migration indices with purified protein derivative as antigen using the standard LMI test and the LMI test performed with purified subpopulations of leucocytes.

**Fig. 6** Effect of incubation with coeliac sera on migration index of normal leucocytes with gluten fraction III as antigen and effect of preincubation with aggregated human IgG.
interaction between its Fc portion and Fc receptors on the cell surface and the blocking of sensitisation of normal leucocytes with coeliac serum by pre-incubation with aggregated IgG supports the contention that cytophilic antibody is present in our system. It is unlikely that immune complexes are responsible for the sensitisation of the normal leucocytes, as their migration in control medium was unaffected by incubation with coeliac serum, inhibition being seen only when gluten was added.

Our results strongly suggest that the direct leucocyte migration inhibition test in coeliac disease seems to measure cytophilic antibody to gluten fractions and not lymphokine production and thus not cell-mediated immunity. The negative skin test results with gluten subfractions and variable results with lymphocyte transformation assays (which may in any case be measuring B lymphocyte transformation) together with our results means that cell-mediated immunity to gluten in coeliac disease cannot be regarded as established. It must be stressed, however, that seemingly minor differences of technique may dramatically affect the results of tests of leucocyte migration and it is possible that lymphokines may be detectable using different methodology. In view of our results, however, it is clear that any such experiments should include controls to exclude migration inhibition mediated by the mechanisms discussed above.

Finally, there is some evidence to suggest that antibody dependent cellular responses to gluten may be pathogenetically important in coeliac disease and in view of our findings further investigation of this possibility seems warranted.

We would like to thank Mr R Hall, Department of Haematology, St James’s Hospital, for performing the differential white cell counts, the staff of the Department of Immunology, St James’s Hospital, for performing the T and B cell counts, and Dr R B Payne for help with statistical analysis.

References

14 Amos HE, Gurner W, Olds RJ, Coombs RRA. Passive sensitisation of tissue cells. II. Ability of cytophilic antibody to render the migration of guinea-pig peritoneal exudate cells inhibitible by antigen. Int Arch Allergy 1967; 32: 496–505.
20 Frazer AC, Fletcher RF, Ross CAC, Shaw B, Sammons HG, Schneider R. Gluten-induced entero-
Leucocyte migration inhibition test in coeliac disease


25 Tizard IR. Macrophage-cytophilic antibodies and the functions of macrophage-bound immunoglobulins.


28 Fidalgo BV, Najjar VA. The physiological role of the lymphoid system. 3. Leucophilic globulin and the phagocytic activity of the polymorphonuclear leucocyte. *Proc Natl Acad Sci USA* 1967; 57: 957–64.


Leucocyte migration inhibition test in coeliac disease - a reappraisal.

F G Simpson, H P Field, P D Howdle, D A Robertson and M S Losowsky

Gut 1983 24: 311-317
doi: 10.1136/gut.24.4.311

Updated information and services can be found at: http://gut.bmj.com/content/24/4/311

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Coeliac disease (537)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/